Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,121.00-2.90%ETH$2,566.72-4.85%GOLD$4,136.70-0.10%OIL$88.94+0.75%
Smart Investors Daily
SID Premium
MD

NASDAQ · MDXG

MiMedx Group, Inc.

Healthcare · Biotechnology

$4.62

Down-$0.01 (-0.22%)

Updated Oct 7, 2026, 8:12 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
26
Dividend yield
0.00%
52-week range
$3.03 – $4.99
Volume
1.05M
Avg. volume
834.24K

Price performance · MDXG

MDXG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

MDXG closed at $4.62 after 21 trading sessions, down 1.07% for the selected period.

Last close
$4.62
Period change
-1.07%
Period low
$4.55
Period high
$4.93
Daily close
View OHLC price history
MDXG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$4.59$4.65$4.48$4.621.05M
Oct 5, 2026$4.58$4.695$4.55$4.55894.73K
Oct 2, 2026$4.69$4.69$4.485$4.591.37M
Oct 1, 2026$4.65$4.68$4.57$4.641.19M
Sep 30, 2026$4.70$4.70$4.565$4.661.03M
Sep 29, 2026$4.65$4.685$4.58$4.67901.2K
Sep 28, 2026$4.655$4.725$4.55$4.68881.3K
Sep 25, 2026$4.71$4.71$4.40$4.671.46M
Sep 24, 2026$4.81$4.82$4.66$4.711.02M
Sep 23, 2026$4.93$4.99$4.67$4.771M
Sep 22, 2026$4.81$4.94$4.78$4.931.03M
Sep 21, 2026$4.79$4.84$4.75$4.81915.91K
Sep 18, 2026$4.65$4.795$4.614$4.773.9M
Sep 17, 2026$4.78$4.79$4.66$4.69935.38K
Sep 16, 2026$4.72$4.765$4.675$4.731.09M
Sep 15, 2026$4.64$4.795$4.58$4.721.15M
Sep 14, 2026$4.60$4.665$4.54$4.64888.92K
Sep 11, 2026$4.64$4.71$4.51$4.57995.85K
Sep 10, 2026$4.65$4.69$4.50$4.601.62M
Sep 9, 2026$4.64$4.70$4.56$4.681.05M
Sep 8, 2026$4.57$4.73$4.43$4.671.06M

Latest MDXG news

The latest Smart Investors Daily articles mentioning MDXG.

Stock researchCompany · Overview

MDXG research

Overview

Company profile and research snapshot.

Company profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.75
Implied upside
—
Analysts
—
MDXG recent ratings
DateFirmRatingTarget
Aug 27, 2026Craig-HallumBuy—
Aug 17, 2026Cantor FitzgeraldOverweight—
Apr 30, 2026CitizensMarket Outperform—
Apr 20, 2026CitizensMarket Outperform—
Apr 17, 2026Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable rul

Yahoo · Sep 8, 2026

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 9, 20261:1 sessions Lake Street BIG10 Best Ideas Growth Conference | New York, NYThursday, September 10, 20261:1 sessions Investors interested in meeting with senior management at these events may contact th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By